Bridge Biotherapeutics Enters into a joint research agreement with the Chinese drug discovery platform company “HitGen” to accelerate the discovery of new drug candidates for a FIC novel cancer therapeutics program Aims to strengthen its oncology portfolio with a novel drug candidate for…